Readmissions in Patients with Cerebral Cavernous Malformations (CCMs): A National Readmission Database (NRD) Study

Akhil Padarti^{*,††,1}, Amod Amritphale^{*,2}, Javed Khader Elias³,
Daniele Rigamonti⁴, Jun Zhang^{††,5}

¹Department of Neurology, University of South Alabama, Mobile, AL 36617 USA

²Department of Neurology, University of South Alabama, Mobile, AL 36617 USA

³Department of Neurosurgery and Radiology, University of New Mexico Health Science,
Albuquerque, NM87131 USA

⁴Department of Neurosurgery, Johns Hopkins Medicine Institutions (JHMI),
Baltimore, MD 21231 USA

⁵Departments of Molecular & Translational Medicine (MTM), Texas Tech University Health
Science Center El Paso (TTUHSCEP), El Paso, TX 79905 USA

Running Title: Readmission Rates in CCM

* Co-first Authors

†† Co-correspondent authors

All correspondence:

Jun Zhang, Sc.D., Ph.D.

Department of Molecular and Translational Medicine (MTM)

Texas Tech University Health Science Center El Paso

5001 El Paso Drive, El Paso, El Paso, TX 79905

Email: jun.zhang2000@gmail.com

Abstract

BACKGROUND: Cerebral cavernous malformations (CCMs) are microvascular CNS lesions prone to hemorrhage leading to neurological sequela such as stroke and seizure. A subset of CCM patients have aggressive disease leading to multiple bleeding events, likely resulting multiple hospitalizations. Hospital admission rates are an important metric that has direct financial impact on hospitals and an indicator of overall disease burden. Furthermore, analysis of hospital readmissions can lead to early identification of high-risk patients and provides insight into the pathogenesis of CCM lesions. The purpose of this study is to identify high risk CCM patients with increased all cause readmission and comorbidities associated with increased readmissions.

METHODS: All US hospital admissions due to CCMs were searched using the 2017 National Readmission Database (NRD). Patients with readmissions within 30 days of discharge from index hospitalization were identified and analyzed, relative to the remaining population.

RESULTS: Among all patients hospitalized for CCM, 14.9% (13.7-16.2%) required all cause readmission within 30 days. Multivariate logistical regression analysis showed that substance abuse ($p=0.003$), diabetes ($p=0.018$), gastrointestinal bleed ($p=0.002$), renal failure ($p=0.027$), and coronary artery disease ($p=0.010$) were predictive of all cause readmissions, while age group 65-74 ($p=0.042$), private insurance ($p<0.001$), and treatment at a metropolitan teaching institution ($p=0.039$) were protective. Approximately half of all readmissions are caused by neurological (33.9%) and infectious (14.6%) etiologies. The 30-day lesion bleeding rate after index hospitalization is 0.8% (0.5-1.2%).

CONCLUSIONS: All identified comorbidities associated with increased risks of readmission contribute to vascular stress, suggesting its role in lesion pathogenesis. This is the first and only study to analyze readmission metrics for CCMs in order to identify high risk patient factors to date.

Abbreviations: Cerebral Cavernous Malformations (CCM), Developmental Venous Anomaly (DVA), National Readmission Database (NRD), Healthcare Cost and Utilization Project (HCUP), Institutional Review Board (IRB), Clinical Classifications Software Refined (CCSR), International Classification of Disease (ICD-10), Interquartile range (IQR), Length of Stay (LOS), All Patient Refined Diagnosis Related Groups (APRDRG), Peripheral Arterial Disease (PAD), Gastrointestinal (GI), Coronary Artery Disease (CAD)

Key Words: Cerebral Cavernous Malformations, Hospital Readmission Rates, National Readmission Database, Lesion Hemorrhage

Introduction

Cerebral cavernous malformations (CCMs) are microvascular lesions predominantly found in the central nervous system, composed of dilated venous sinusoids with a singular layer of endothelium and minimal intervening brain parenchyma. CCMs are the second most common cerebral vascular abnormality following developmental venous anomaly (DVA) ¹. It is estimated that CCM lesions are present in 1 in 200-600 in the general population with higher prevalence in Hispanic population (1 in 70) ²⁻⁴. These lesions are predisposed to hemorrhagic strokes and seizures ⁵. Patients exhibit a wide range of disease severity depending on the underlying gene mutation, lesion burden, location, and frequency of hemorrhage. A substantial number of patients with CCMs are asymptomatic (20-70%) ⁶⁻⁸.

However symptomatic patients can have devastating neurological deficits often due to CCM lesion bleeding. If the frequency of lesion bleeding can be reduced, then the quality of life for CCM patients could be drastically improved. It has been shown that patients with one bleeding event have an increased risk (>10%) for a recurrent bleeding event ^{9, 10}. Therefore, one subset of CCM patients have asymptomatic lesions while another subset have aggressive lesions with multiple hemorrhages. Identifying common factors unique to patients with aggressive disease will not only help clinicians distinguish high-risk patients, but also the shared characteristics may provide insight into CCM lesion pathogenesis.

Readmission rates are important hospital metrics used to gauge quality of healthcare received and have direct financial implications ¹¹. CCM patients with aggressive phenotypes are more likely to incur admissions and readmissions to hospitals. Analyzing readmission rates will help identify

CCM patients with high lesion burden in efforts that may lead to decreasing future hospitalizations. To date, this is the only study on CCM readmission rates to identify high risk CCM patients. The purpose of this study is to identify high risk CCM patients with increased all cause readmission and associated comorbidities.

Materials and methods

National Readmission Database. This study examined CCM readmissions using hospital admissions data from the National Readmission Database (NRD), Healthcare Cost and Utilization Project (HCUP), Agency for Healthcare Research and Quality, for 2017¹². This is largest publicly available national representative sample of all admissions and discharges from U.S. nonfederal hospitals provided by the Agency of Healthcare Research and Quality. It contains data from 28 geographically dispersed states across the U.S (www.hcup-us.ahrq.gov/hcupdatapartners.jsp). It has about 18 million discharges for the year 2017. This database contains hospitalizations from 60% of the U.S. population. A unique de-identified linkage number is assigned to each patient which tracks readmissions within the same state.

Patient Determination. CCM was defined with the diagnosis codes from CCSR/ICD-10 (supplementary table 1). Index hospitalization is any patient non-electively admitted to the hospital with a primary admission diagnosis of CCMs. The primary outcome variable was the first non-elective readmission within 30 days after discharge from index hospitalization. Only the first of these readmissions was included in the analysis. Exclusion criteria include any admission in December 2017 as they were not followed up for at least 30 days (no access to 2018 data), patients that died during the initial hospitalization, or had missing data for discharge. The study used

publicly available deidentified database and was approved for exempt status by the University of South Alabama Institutional Review Board (IRB). Our study followed the methodology as previously utilized in other studies ^{13, 14}.

Clinical Variables. Pertinent patient demographics were obtained by NRD variables: age, sex, weekend admission, insurance status, and quartile of household income (Table 1). The quartile of household income was determined by ZIP code demographic data. Cost analysis of the repeat admission was performed by analyzing data on index admission length of stay (LOS) (days), index admission cost (U.S. dollar), and discharge destination (Table 1). Hospital charges were multiplied with the Agency for Healthcare Research and Quality's all-payer cost-to-charge ratios to determine costs. The burden of the CCM lesions was measured by risk of mortality and loss of function subclasses in the index hospitalization (Table 1). Baseline patient comorbidities during the index hospitalization were determined by CCSR/ICD-10 codes shown in supplementary table 1. The first diagnosis CCSR/ICD-10 code was determined to be cause of the readmission (Table 4). All CCSR/ICD-10 codes used in this study are presented in the supplemental section.

Statistical Analysis. Statistical analysis was performed using SPSS-1.0.0.118 (IBM Corp., Armonk, N.Y., USA). Two-sided *t*-test was used for statistical analysis. Baseline characteristics between non-readmission and readmission patients were tested for statistical differences using the Pearson Chi Square test for categorical variables and Mann-Whitney U-Test for continuous variables, with non-readmission as the reference group. Multivariable logistic regression analysis was performed on all cause readmission to determine the predictors of readmission, with adjustments for age-group, gender, insurance status, hospital teaching status, and comorbidities

(Table 3). Statistical significance was defined by p-value (0.05 *, 0.01 **, 0.001 ***).

Results

All-Cause Readmission Rate for Cerebral Cavernous Malformations (CCMs). There were a total of 1881 admissions (3382 weighted) in the 2017 NRD database due to CCMs. 286 (504 weighted) of these patients had an unplanned readmission within 30 days of discharge. NRD recommends using weighted figures to estimate national prevalence in order to increase external validity of the analysis and protect patient privacy. The 30 day all cause readmission rate was 14.9% (13.7-16.2%) (Fig. 1). The frequency of readmission decreased over the 30 days after discharge, with most readmissions occurring within the first week (Fig. 2).

Baseline Patient Characteristics for All Cause Readmissions. The baseline characteristics for the index hospitalization is shown in Table 1. The majority of patients in this study were women (55.7%) aged 42-72, consistent with previous reported dimorphisms of CCM severity, with increased severity in females ^{15, 16}. However, there were no statistically differences seen with gender (p=0.053) and age (p=0.248). The cost of the index hospitalization (p<0.001) and length of index hospitalization (p<0.001) were significantly higher in readmitted patients. Readmitted patients were more likely to have Medicare and Medicaid and less likely to have private insurance. There were no differences in the income quartile between readmitted and non-readmitted patients. Patients with higher risk of mortality (p<0.001) and loss of function (p<0.001) were more likely to get readmitted in a severity-dependent manner. Patients seen at smaller sized hospitals were more likely to get readmitted than a larger sized hospital (p=0.012). Patients seen at non-teaching metropolitan hospitals were readmitted more frequently than teaching metropolitan hospitals

($p=0.036$), suggesting that quality of healthcare may have impact on readmission rates. Patients that were discharged home were less likely to get readmitted while patient set up with home health, short-term, or long-term care facility were more likely to get readmitted ($p<0.001$).

Patient Comorbidities for All Cause Readmission Rates. The effect of patient comorbidities on all cause readmission rates is shown in Table 2. Statistically significant higher readmission rates were seen in patients with substance use ($p=0.028$), lipid disorders ($p=0.046$), diabetes ($p<0.001$), GI bleeding ($p<0.001$), coagulation disorders ($p=0.019$), renal failure ($p<0.001$), and CAD ($p<0.001$). Interestingly, significantly lower readmission rates were seen in patients with tobacco use ($p=0.028$), dermatological lesions ($p=0.029$), and headaches ($p=0.039$). No difference was observed in other neurological comorbidities such as seizures, ischemic stroke, and hemorrhagic stroke (Table 2).

Predictors of All Cause Readmissions. In multivariable logistic regression analysis (Table 3), only one age group (65-74) had significantly fewer readmissions than the reference population (>75). Private insurance (OR 0.441, $p<0.001$) was protective of readmissions, relative to Medicaid, while there were no differences seen among Medicare, self-pay, no charge, and other insurances. Metropolitan teaching hospitals (OR 0.769, $p=0.039$) decreased odds of readmission relative to non-teaching metropolitan hospitals. Several comorbidities including substance use (OR 1.805, $p=0.003$), diabetes (OR 1.335, $p=0.018$), GI bleeding (OR 3.427, $p=0.002$), renal failure (OR 1.432, $p=0.027$), and CAD (1.429, $p=0.010$) significantly increased odds of readmission, while none of the neurological comorbidities (seizures, ischemic stroke, hemorrhagic stroke, and headache) affected readmission odds.

Etiology of 30-Day Readmissions. The primary diagnosis for each readmission is grouped by organ-based system (Table 4). As expected, the most common organ system resulting in readmission is neurological complications (33.9%). The most frequent readmission diagnosis is septicemia (8.3%), while the most frequent neurological diagnosis was acute hemorrhagic cerebrovascular disease (5.2%). The 30-day CCM lesion hemorrhage rate is 0.8% (0.5-1.2%) after index hospitalization.

Discussion

Overall, 30-day all cause readmission rate for CCM patients was 14.9%, approximately one in seven CCM patients, slightly worse than the national average hospital readmission rate (13.9%) and national readmission rate due to neurological conditions (14.0%)¹⁷. To date, there is no effective medication for delaying the progression of CCM lesions, likely hindering disease management, and thereby increasing hospital readmission rates in CCM patients relative to the general population¹⁸.

Female gender has been associated with worse outcomes in CCM patients^{15, 16}. This similar phenomenon was seen in the analysis in which a majority of the hospitalized patients are female (55.7%) (Table 1). However, female gender was not predictive of readmissions (Table 3). This analysis, in concordance with previous studies, suggests that women are more likely to have severe CCM disease necessitating initial hospitalizations, however both genders with active CCM lesions are equally likely to require readmission. This association between CCM disease severity and female gender has been known for decades, yet it was only recently that an explanation was

discovered. One study has shown that progesterone plays a crucial role in CCM protein signaling and increased exposure to progesterone and its derivatives (progestins) may lead to increased bleeding rates of CCM lesions leading to increased hospitalizations^{19,20}. In the general population, older patients have more frequent readmissions than younger patients. However this is not seen in CCM patient population¹⁷. Accounting for comorbidities, there was a small significant decrease in readmissions in the middle-aged group (65-74) relative to the reference (Table 4). Our analysis showed that CCM readmission frequency by age is bimodal likely due to multitude of CCM genetic mutations resulting in the variable age of disease onset. Therefore, younger patients may have aggressive mutations requiring frequent readmissions while older patients, due to decreased organ reserve, may require readmission even with milder CCM phenotypes. Patients with private insurance have significantly decreased readmission rates relative to all other insurance types, which may be attributed to the increased access to outpatient resources.

Patients with readmissions had a significantly larger index hospitalization cost and index hospitalization length of stay (Table 1). This suggests that these patients had more severe presentations of the disease leading to more readmissions, which was confirmed when stratifying the patients by APRDRG functionality class and mortality class. Readmitted patients had a significantly lower baseline functionality and higher mortality risk, suggesting that severe disease leads to more readmissions. This has been shown in the general population¹⁷. Patients treated at metropolitan teaching hospitals with higher bed capacity had lower readmission rates, implying that the quality of healthcare affected readmission rates (Table 3). Several large teaching hospitals in the country have been designated CCM centers for excellence, including Barrow Neurological Institute, University of Chicago, University of Virginia, University of New Mexico, Mayo Clinic,

etc. All of these centers of excellence are teaching hospitals, where well-trained neurosurgeons and neurologists provide specialized care for CCM patients. This analysis suggests that treatment at these larger teaching hospitals significantly decreased readmission rates.

Certain patient comorbidities could predict which CCM patient would require readmission. Some comorbidities were seen in higher frequency in readmitted patients of which coronary artery disease (CAD), diabetes, renal failure, and substance abuse were predictive of readmission in the regression analysis (Table 2, 3). CAD ²¹, diabetes ²², renal failure ²³, and substance abuse of certain drugs ²⁴ have been shown to generate free radicals that could result in vascular stress and damage to certain regions of the vasculature, possibly triggering the formation of new CCM lesions. This may explain why certain lesions are more predisposed to bleeding, while other lesions remain clinically silent. Interestingly, this did not extend to all comorbidities associated with vascular stress including tobacco use and lipid disorders, suggesting that more research is needed to understand why only certain factors play major roles in readmissions. Patients with GI bleeds were found to be predictive of readmission. CCM lesions have been seen in other organs such as liver, bone, skin, and lungs but they are often only clinically significant in the CNS ²⁵. Patient with history of bleeding in other organ systems may be predisposed to readmission.

The role of pregnancy in CCM disease is a disputed with some reporting no increased disease activity ²⁶⁻²⁸, while others suggesting there is increased activity ²⁹. There are not enough pregnant patients to perform statistical testing, however no effect was seen in logistical regression analysis (Table 2,3). A proposed mechanism of CCM pathogenesis is infections and alteration of the microbiome ^{30,31}. Certain infections lead to innate immunogenic responses, such as TLR4, which

was reported to result in CCM lesions ³⁰. This analysis did not show any effect of infection on all cause readmission rates (Table 3). Although neurological conditions were found to be a major cause for readmission, previous history of seizures and strokes were not predictive of readmission. Patients with CCM lesions can also develop cutaneous lesions and headaches. Although headaches were seen in higher frequency among readmitted patients and dermatological lesions were seen in lower frequency among readmitted patients, there was no effect in all cause readmissions after accounting for other variables (Table 3). This is likely due to diagnoses of headache and skin lesions being non-specific for CCM disease even in CCM patients.

Analysis of all cause readmission etiologies showed that the most common primary causes of readmissions were neurological (33.9%) and infectious (14.6%). Patients with CCMs have a wide range of neurological sequelae including hemorrhagic cerebrovascular accident, seizures, and headaches ³². In this analysis, seizures (5.2%) and hemorrhage (4.9%) were similar in frequency. The 30-day lesion bleeding rate after index hospitalization is 0.8% (0.5-1.2%). Treatment of these sequelae requires better management of the underlying CCM disease. Hospital-acquired infectious etiologies are the second most frequent cause of readmissions in CCM patients. Hospitalized patients are prone to getting subsequent infections, and CCM patients may be at higher risk due to neurological disability requiring devices such as foleys. Timely removal of unnecessary devices may decrease readmission due to infectious etiologies. Other etiologies of all cause readmission were gastrointestinal (5.8%), cardiac (5.4%), and pulmonary (4.9%), unlikely to be related directly to CCM pathology and improved patient follow up may decrease readmissions from these etiologies.

The objective of this study is to utilize the NRD to identify risk factors associated with high risk CCM patients for 30-day readmission. If these patients are identified in the primary admission, it may be possible to allocate more resources to prevent future readmissions. Decreasing hospital readmissions not only decreases healthcare burden due to CCMs, but also improves patient quality of life. Future studies may consider using artificial intelligence and machine learning to develop algorithms and plugins for patient care software that will help clinicians implement new therapeutic strategies to improve the quality of patient care and healthcare outcomes¹³. We also hope that by identifying similar characteristics among patients with aggressive CCM disease, it would increase understanding of the pathogenesis of CCM lesions. This methodology has been used to study other neurological diseases^{33, 34}. However, there are still limitations that must be taken in account. The NRD database is a readmission database that stores patient ICD-10 diagnosis codes for each hospitalization. Any patient that was only seen in the emergency department without hospital admission would not be included in the database. There are limitations to the elements documented in the database. Certain CCM lesion characteristics such as number of lesions, size of lesion, and location of lesion are influential in the severity of CCM disease³⁵. However, the NRD does not provide any information on these factors. Although ICD-10 codes increase the accuracy of diagnosis, inaccuracies and misdiagnoses are still possible. ICD-10 diagnostic code ‘D1802’ (hemangioma of intracranial vessels) is the most specific diagnosis for CCM, however as evidenced by readmission etiologies, few patients were diagnosed with ‘Q283’ (Other malformations of cerebral vessels). Therefore, few patients with CCM may be in this other diagnostic category. Some inaccuracies are to be expected in analyzing such large databases. Additionally, CCM is a rare disease, although its prevalence is increasing due to accessibility of MRI imaging. Even in the NRD, which encompasses 60% of all inpatient admissions in the USA,

there are not enough readmitted patients with certain comorbidities such as pregnancy to adequately power the statistical test to identify a difference. Lastly, this is a retrospective observational study and therefore causation cannot be inferred from the data.

Conclusion

This study is the first and only study analyzing readmission rates in CCM patients, with such a substantial sample size. Readmission rates have gathered popularity in the last several years and have direct financial implications to healthcare facilities and in allocation of resources. Decreasing readmissions would decrease the financial burden of CCM lesions and improve overall patient quality of life. In this study, several patient characteristics and comorbidities were identified that increased the odds of readmission. Future efforts include intervening on high-risk patients for readmission and reassessment of disease burden on CCM patients.

REFERENCES

1. Batra S, Lin D, Recinos PF, Zhang J, Rigamonti D. Cavernous malformations: natural history, diagnosis and treatment. *Nat Rev Neurol*. 2009 Dec;5(12):659-70. PubMed PMID: 19953116. Epub 2009/12/03.
2. Caton MT, Shenoy VS. Cerebral Cavernous Malformations. *StatPearls*. Treasure Island (FL)2021.
3. Flemming KD, Graff-Radford J, Aakre J, Kantarci K, Lanzino G, Brown RD, Jr., et al. Population-Based Prevalence of Cerebral Cavernous Malformations in Older Adults: Mayo Clinic Study of Aging. *JAMA Neurol*. 2017 Jul 1;74(7):801-5. PubMed PMID: 28492932. Pubmed Central PMCID: PMC5647645. Epub 2017/05/12.
4. Gunel M, Awad IA, Finberg K, Steinberg GK, Craig HD, Cepeda O, et al. Genetic heterogeneity of inherited cerebral cavernous malformation. *Neurosurgery*. 1996 Jun;38(6):1265-71. PubMed PMID: 8727164. Epub 1996/06/01.
5. Gross BA, Du R. Cerebral cavernous malformations: natural history and clinical management. *Expert Rev Neurother*. 2015;15(7):771-7. PubMed PMID: 26098013. Epub 2015/06/23.
6. Choquet H, Trapani E, Goitre L, Trabalzini L, Akers A, Fontanella M, et al. Cytochrome P450 and matrix metalloproteinase genetic modifiers of disease severity in Cerebral Cavernous Malformation type 1. *Free Radic Biol Med*. 2016 Mar;92:100-9. PubMed PMID: 26795600. Pubmed Central PMCID: PMC4774945. Epub 2016/01/23.
7. Moore SA, Brown RD, Jr., Christianson TJ, Flemming KD. Long-term natural history of incidentally discovered cavernous malformations in a single-center cohort. *J Neurosurg*. 2014 May;120(5):1188-92. PubMed PMID: 24628608. Epub 2014/03/19.

8. Spiegler S, Rath M, Paperlein C, Felbor U. Cerebral Cavernous Malformations: An Update on Prevalence, Molecular Genetic Analyses, and Genetic Counselling. *Mol Syndromol*. 2018 Feb;9(2):60-9. PubMed PMID: 29593473. Pubmed Central PMCID: PMC5836221. Epub 2018/03/30.
9. Barker FG, 2nd, Amin-Hanjani S, Butler WE, Lyons S, Ojemann RG, Chapman PH, et al. Temporal clustering of hemorrhages from untreated cavernous malformations of the central nervous system. *Neurosurgery*. 2001 Jul;49(1):15-24; discussion -5. PubMed PMID: 11440436. Epub 2001/07/07.
10. Flemming KD, Link MJ, Christianson TJ, Brown RD, Jr. Prospective hemorrhage risk of intracerebral cavernous malformations. *Neurology*. 2012 Feb 28;78(9):632-6. PubMed PMID: 22302553. Epub 2012/02/04.
11. Upadhyay S, Stephenson AL, Smith DG. Readmission Rates and Their Impact on Hospital Financial Performance: A Study of Washington Hospitals. *Inquiry*. 2019 Jan-Dec;56:46958019860386. PubMed PMID: 31282282. Pubmed Central PMCID: PMC6614936. Epub 2019/07/10.
12. HCUP Nationwide Readmissions Database (NRD). Healthcare Cost and Utilization Project (HCUP). 2017. Agency for Healthcare Research and Quality, Rockville, MD. www.hcup-us.ahrq.gov/nrdoverview.jsp [database on the Internet].
13. Amritphale A, Chatterjee R, Chatterjee S, Amritphale N, Rahnavard A, Awan GM, et al. Predictors of 30-Day Unplanned Readmission After Carotid Artery Stenting Using Artificial Intelligence. *Advances in Therapy*. 2021 2021/04/09.
14. Sehgal M, Custodio H, Amritphale N, Davis N, Vidal R, Amritphale A. 1212: Demographics Characteristics and Risk Factors for 30-Day Unplanned Pediatric Sepsis

Readmissions. Critical Care Medicine. 2021;49(1):609. PubMed PMID: 00003246-202101001-01180.

15. Porter RW, Detwiler PW, Spetzler RF, Lawton MT, Baskin JJ, Derksen PT, et al. Cavernous malformations of the brainstem: experience with 100 patients. J Neurosurg. 1999 Jan;90(1):50-8. PubMed PMID: 10413155. Epub 1999/07/21.

16. Aiba T, Tanaka R, Koike T, Kameyama S, Takeda N, Komata T. Natural history of intracranial cavernous malformations. J Neurosurg. 1995 Jul;83(1):56-9. PubMed PMID: 7782850. Epub 1995/07/01.

17. Bailey MK, Weiss AJ, Barrett ML, Jiang HJ. Characteristics of 30-Day All-Cause Hospital Readmissions, 2010-2016: Statistical Brief #248. Healthcare Cost and Utilization Project (HCUP) Statistical Briefs. Rockville (MD)2006.

18. Dalyai RT, Ghobrial G, Awad I, Tjoumakaris S, Gonzalez LF, Dumont AS, et al. Management of incidental cavernous malformations: a review. Neurosurg Focus. 2011 Dec;31(6):E5. PubMed PMID: 22133177. Epub 2011/12/03.

19. Abou-Fadel J, Jiang X, Padarti A, Goswami D, Smith M, Grajeda B, et al. CCM signaling complex (CSC) is a master regulator governing homeostasis of progestins and their mediated signaling cascades. bioRxiv. 2020:2020.06.10.145003.

20. Abou-Fadel J, Jiang X, Grajeda B, Padarti A, Ellis CC, Zhang J. CCM signaling complex (CSC) coupling both classic and non-classic progesterone receptor signaling. bioRxiv. 2020:2020.05.24.112847.

21. Christodoulidis G, Vittorio TJ, Fudim M, Lerakis S, Kosmas CE. Inflammation in coronary artery disease. Cardiol Rev. 2014 Nov-Dec;22(6):279-88. PubMed PMID: 24441047. Epub 2014/01/21.

22. Tsalamandris S, Antonopoulos AS, Oikonomou E, Papamikroulis GA, Vogiatzi G, Papaioannou S, et al. The Role of Inflammation in Diabetes: Current Concepts and Future Perspectives. *Eur Cardiol*. 2019 Apr;14(1):50-9. PubMed PMID: 31131037. Pubmed Central PMCID: PMC6523054. Epub 2019/05/28.
23. Mihai S, Codrici E, Popescu ID, Enciu AM, Albulescu L, Necula LG, et al. Inflammation-Related Mechanisms in Chronic Kidney Disease Prediction, Progression, and Outcome. *J Immunol Res*. 2018;2018:2180373. PubMed PMID: 30271792. Pubmed Central PMCID: PMC6146775. Epub 2018/10/03.
24. Fox HC, D'Sa C, Kimmerling A, Siedlarz KM, Tuit KL, Stowe R, et al. Immune system inflammation in cocaine dependent individuals: implications for medications development. *Hum Psychopharmacol*. 2012 Mar;27(2):156-66. PubMed PMID: 22389080. Pubmed Central PMCID: PMC3674778. Epub 2012/03/06.
25. Mespreuve M, Vanhoenacker F, Lemmerling M. Familial Multiple Cavernous Malformation Syndrome: MR Features in This Uncommon but Silent Threat. *J Belg Soc Radiol*. 2016 Mar 21;100(1):51. PubMed PMID: 30151459. Pubmed Central PMCID: PMC6100658. Epub 2016/03/21.
26. Kalani MY, Zabramski JM. Risk for symptomatic hemorrhage of cerebral cavernous malformations during pregnancy. *J Neurosurg*. 2013 Jan;118(1):50-5. PubMed PMID: 23039155. Epub 2012/10/09.
27. Witiw CD, Abou-Hamden A, Kulkarni AV, Silvaggio JA, Schneider C, Wallace MC. Cerebral cavernous malformations and pregnancy: hemorrhage risk and influence on obstetrical management. *Neurosurgery*. 2012 Sep;71(3):626-30; discussion 31. PubMed PMID: 22710379. Epub 2012/06/20.

28. Joseph NK, Kumar S, Brown RD, Jr., Lanzino G, Flemming KD. Influence of Pregnancy on Hemorrhage Risk in Women With Cerebral and Spinal Cavernous Malformations. *Stroke*. 2021 Jan;52(2):434-41. PubMed PMID: 33493052. Epub 2021/01/26.
29. Yamada S, Nakase H, Nakagawa I, Nishimura F, Motoyama Y, Park YS. Cavernous malformations in pregnancy. *Neurol Med Chir (Tokyo)*. 2013;53(8):555-60. PubMed PMID: 23979052. Epub 2013/08/28.
30. Tang AT, Sullivan KR, Hong CC, Goddard LM, Mahadevan A, Ren A, et al. Distinct cellular roles for PDCD10 define a gut-brain axis in cerebral cavernous malformation. *Sci Transl Med*. 2019 Nov 27;11(520). PubMed PMID: 31776290. Pubmed Central PMCID: PMC6937779. Epub 2019/11/30.
31. Polster SP, Sharma A, Tanes C, Tang AT, Mericko P, Cao Y, et al. Permissive microbiome characterizes human subjects with a neurovascular disease cavernous angioma. *Nat Commun*. 2020 May 27;11(1):2659. PubMed PMID: 32461638. Pubmed Central PMCID: PMC7253448. Epub 2020/05/29.
32. Akers A, Al-Shahi Salman R, A. Awad I, Dahlem K, Flemming K, Hart B, et al. Synopsis of Guidelines for the Clinical Management of Cerebral Cavernous Malformations: Consensus Recommendations Based on Systematic Literature Review by the Angioma Alliance Scientific Advisory Board Clinical Experts Panel. *Neurosurgery*. 2017;80(5):665-80.
33. Patel S, SirDeshpande P, Desai R, Desai N, Mistry H, Patel N, et al. Thirty-day readmissions in multiple sclerosis: An age and gender-based US national retrospective analysis. *Mult Scler Relat Disord*. 2019 Jun;31:41-50. PubMed PMID: 30925319. Epub 2019/03/30.
34. Edla S, Atti V, Kumar V, Tripathi B, Neupane S, Nalluri N, et al. Comparison of nationwide trends in 30-day readmission rates after carotid artery stenting and carotid

endarterectomy. J Vasc Surg. 2020 Apr;71(4):1222-32 e9. PubMed PMID: 31564583. Epub 2019/10/01.

35. Gross BA, Du R. Hemorrhage from cerebral cavernous malformations: a systematic pooled analysis. J Neurosurg. 2017 Apr;126(4):1079-87. PubMed PMID: 27203143. Epub 2016/05/21.

Legends

Figure 1: Flowchart of CCM patient selection and overall study design

Inclusion criteria are all patients admitted in US hospitals with primary diagnosis of CCM in 2017. Exclusion criteria are patients with death during the index hospitalization, missing data on index discharge, and admitted in December 2017. Patients were weighted to estimate national admission levels as recommended by Health Care Utilization Project (HCUP). Readmission is defined as any patient readmitted to the hospital within 30 days of discharge. Any patients admitted under observation and seen in the emergency room were not included.

Figure 2: Probability Distribution Plot of All Cause Readmissions

The bar graph represents the frequency of readmissions per day after discharge from index hospitalizations. The probability distribution line graph shows the probability density of readmissions. (Mean = 11.19, Std. Dev = 8.5, N = 509)

Table 1: CCM Patient Characteristics during Index Hospitalization for All Cause Readmission

Baseline patient characteristics from NRD are shown i.e. age, gender, weekend admission, true cost of hospitalization, length of stay, insurance status, quartile of median household income, APRDRG: likelihood of dying, APRDRG: loss of function, hospital bed size, hospital teaching status, discharge location, control/ownership of hospital, and hospital designation. Age, true cost of hospitalization, and length of stay is presented as median and interquartile range (IQR), while all other discrete characteristics are presented as percentages. Characteristics of patients without all cause 30-day readmission (first column), with all cause 30-day readmission (second column),

and total patient population (third column) are shown. The p-value for the characteristic between the two groups is also shown (fourth column). All significant p-values are bolded. The cutoffs of quartile of median household income, APRDRG: likelihood of dying, APRDRG: loss of function, and hospital bed size were defined as per HCUP. All data shown is weighted values in order to maintain patient privacy. Abbreviations: IQR-Interquartile range, LOS-length of stay, APRDRG-all patient refined diagnosis related groups. * $p<0.05$, ** $p<0.01$, *** $p<0.001$.

Table 2: Comorbidities in CCM patients with 30 day all cause readmissions

Patient baseline comorbidities without all cause 30-day readmission (first column), with all cause 30-day readmission (second column), and total patient population (third column) are shown. The p-value for the characteristic between the two groups is also shown (fourth column). Each cell shows the weighted number of patients and percentage, as recommended by HCUP. Data from any cell with $N<5$ is removed as per HCUP requirements. All significant p-values are bolded. Skin lesions represent all dermatological abnormalities, non-specific for CCMs. All CCSR codes used to define the comorbidities are shown in supplementary table 1. Abbreviations: CCSR-Clinical Classifications Software Refined, CAD-coronary artery disease, GI-gastrointestinal, PAD-peripheral arterial disease. * $p<0.05$, ** $p<0.01$, *** $p<0.001$.

Table 3: Multivariable logistic regression analysis for all cause readmission due to CCMs

Multivariate logistical regression analysis with variables of age, gender, insurance status, hospital teaching status, and comorbidities is shown. The odds ratio and its 95% confidence interval is shown (column 2). The p-value for the characteristic between the two groups is also shown (third column). The reference group for age, gender, insurance status, and hospital teaching status is

designated. All significant p-values are bolded. All CCSR codes used to define the comorbidities are shown in supplementary table 1. Abbreviations: CCSR-Clinical Classifications Software Refined, CAD-coronary artery disease, GI-gastrointestinal, PAD-peripheral arterial disease. *p<0.05, **p<0.01, ***p<0.001.

Table 4: Etiology of All Cause 30-Day Readmission in CCMs

The majority of primary diagnoses for all cause 30-day readmission after index hospitalization are shown. The primary default CCSR category is shown for each admission. The percentage of patients readmitted for each diagnosis is detailed. The diagnoses are grouped by organ system involved.

**Supplementary Table 1: Clinical Classifications Software Refined (CCSR) codes for CCM
and associated comorbidities**

All the CCSR/ICD-10 codes used in this study for each comorbidity are shown.

Table 1: CCM Patient Characteristics during Index Hospitalization for All Cause Readmission

	No 30d readmission N (%)	30d readmission N (%)	Overall N (%)	P Value
Age(in years), median [IQR]	58 (42-71)	65 (49-77)	58 (42-72)	0.248
Women	1624 (56.4%)	261 (51.8%)	1885 (55.7%)	0.053
Weekend admission	579 (20.1%)	123 (24.4%)	702 (20.8%)	0.029*
Cost of hospitalization in US\$, median [IQR]	9200 (5500-18700)	10100 (6000-21500)	9300 (5600-19200)	<0.001***
LOS, median [IQR]	3 (2-5)	4 (2-7)	3 (2-5)	<0.001***
Insurance status				<0.001***
Medicare	1191 (41.4%)	286 (56.9%)	1477 (43.7%)	
Medicaid	395 (13.7%)	82 (16.3%)	477 (14.1%)	
Private	1071 (37.3%)	99 (19.7%)	1170 (34.6%)	
Self-pay	107 (3.7%)	19 (3.8%)	126 (3.7%)	
No charge	12 (0.4%)	-	12 (0.4%)	
Other	98 (3.4%)	17 (3.4%)	115 (3.4%)	
Quartile of median household income				0.167
0-25th	672 (23.6%)	134 (27.3%)	806 (24.1%)	
26th-50th	840 (29.5%)	134 (27.3%)	974 (29.2%)	
51st-75th	678 (23.8%)	124 (25.3%)	802 (24.0%)	
76th-100th	659 (23.1%)	99 (20.2%)	758 (22.7%)	
APRDRG, Likelihood of dying				<0.001***
Minor	1293 (44.9%)	141 (27.9%)	1434 (42.4%)	
Moderate	858 (29.8%)	151 (29.9%)	1009 (29.8%)	
Major	540 (18.8%)	158 (31.3%)	698 (20.6%)	
Extreme	188 (6.5%)	55 (10.9%)	243 (7.2%)	
APRDRG, Loss of function				<0.001***
Minor (includes cases with no comorbidity or complications)	521 (18.1%)	57 (11.3%)	578 (17.1%)	
Moderate	1334 (46.4%)	197 (39.2%)	1531 (45.3%)	
Major	843 (29.3%)	182 (36.2%)	1025 (30.3%)	
Extreme	180 (6.3%)	67 (13.3%)	247 (7.3%)	
Hospital bed size				0.012*
Small	229 (8.0%)	59 (11.7%)	288 (8.5%)	
Medium	684 (23.8%)	125 (24.9%)	809 (23.9%)	
Large	1965 (68.3%)	319 (63.4%)	2284 (67.6%)	
Hospital teaching status				0.036*
Metropolitan, non-teaching	455 (15.8%)	103 (20.4%)	558 (16.5%)	
Metropolitan, teaching	2308 (80.2%)	382 (75.8%)	2690 (79.6%)	
Non-metropolitan	114 (4.0%)	19 (3.8%)	133 (3.9%)	
Discharge location				<0.001***
Home self care	2012 (69.9%)	301 (59.8%)	2313 (68.4%)	
Home health care	30 (1.0%)	6 (1.2%)	36 (1.1%)	
Transfer to short-term hospital	406 (14.1%)	112 (22.3%)	518 (15.3%)	
Transfer to other care facility	398 (13.8%)	70 (13.9%)	468 (13.8%)	
Against medical advice	32 (1.1%)	14 (2.8%)	46 (1.4%)	
Control/Ownership of hospital				0.850
Government	311 (10.8%)	54 (10.7%)	365 (10.8%)	
Private non-profit	2257 (78.4%)	399 (79.3%)	2656 (78.6%)	
Private for-profit	310 (10.8%)	50 (9.9%)	360 (10.6%)	
Hospital Designation				0.946

Large metropolitan, ≥1 million residents	1826 (63.4%)	322 (64.0%)	2148 (63.5%)	
Small metropolitan, ≤1 million residents	938 (32.6%)	163 (32.4%)	1101 (32.6%)	
Micropolitan	83 (2.9%)	14 (2.8%)	97 (2.9%)	
Non-urban residual	31 (1.1%)	-	35 (1.0%)	

Table 2: Comorbidities in CCM patients with 30 day all cause readmissions

Comorbidities	No 30d readmission N (%)	30d readmission N (%)	Overall N (%)	P value
Alcohol Use	180 (6.3%)	24 (4.8%)	204 (6.0%)	0.197
CAD	365 (12.7%)	109 (21.6%)	474 (14.0%)	<0.001***
Coagulation disorders	167 (5.8%)	43 (8.5%)	210 (6.2%)	0.019**
Diabetes	532 (18.5%)	142 (28.2%)	674 (19.9%)	<0.001***
GI Bleed	17 (0.6%)	11 (2.2%)	28 (0.8%)	<0.001***
Headache	375 (13.0%)	49 (9.7%)	424 (12.5%)	0.039*
Hypertension	1175 (40.8%)	213 (42.3%)	1388 (41.0%)	0.546
Hemorrhagic stroke	508 (17.7%)	88 (17.5%)	596 (17.6%)	0.917
Ischemic stroke	273 (9.5%)	53 (10.5%)	326 (9.6%)	0.470
Infections	285 (9.9%)	48 (9.5%)	333 (9.8%)	0.803
Lipid disorders	928 (32.2%)	185 (36.8%)	1113 (32.9%)	0.046*
Obesity	348 (12.1%)	71 (14.1%)	419 (12.4%)	0.204
PAD	106 (3.7%)	22 (4.4%)	128 (3.8%)	0.454
Pregnancy	72 (2.5%)	-	76 (2.2%)	-
Renal Failure	268 (9.3%)	84 (16.7%)	352 (10.4%)	<0.001***
Seizures	758 (26.3%)	130 (25.8%)	888 (26.3%)	0.798
Skin lesions	173 (6.0%)	18 (3.6%)	191 (5.6%)	0.029*
Substance abuse	152 (5.3%)	39 (7.7%)	191 (5.6%)	0.028*
Tobacco use	408 (14.2%)	53 (10.5%)	461 (13.6%)	0.028*

Table 3: Multivariable logistic regression analysis for all cause readmission due to CCMs

Variable	OR (95% CI)	P value
Age		
≥75	1 (reference)	
18-44	0.720 (0.472-1.097)	0.126
45-64	0.704 (0.495-1.002)	0.051
65-74	0.744 (0.560-0.990)	0.042*
Gender		
Male	1 (reference)	
Female	0.842 (0.687-1.031)	0.096
Insurance status		
Medicaid	1 (reference)	
Medicare	0.816 (0.567-1.173)	0.272
Private insurance	0.441 (0.318-0.610)	<0.001***
Self-pay	0.802 (0.459-1.402)	0.440
No charge	-	
Other	0.855 (0.482-1.518)	0.593
Hospital teaching status		
Metropolitan, non-teaching	1 (reference)	
Metropolitan, teaching	0.769 (0.599-0.987)	0.039*
Non-metropolitan	0.665 (0.383-1.153)	0.146
Comorbidities		
Tobacco use	0.723 (0.521-1.003)	0.052
Alcohol use	0.789 (0.497-1.253)	0.315
Substance abuse	1.805 (1.217-2.678)	0.003*
Lipid disorders	0.861 (0.684-1.082)	0.199
Hypertension	1.054 (0.839-1.324)	0.652
Diabetes	1.335 (1.050-1.697)	0.018*
Obesity	1.130 (0.842-1.518)	0.415
PAD	0.914 (0.561-1.489)	0.718
GI Bleed	3.427 (1.544-7.603)	0.002**
Coagulation disorders	1.329 (0.918-1.922)	0.131
Infections	0.762 (0.544-1.067)	0.113
Renal Failure	1.432 (1.042-1.970)	0.027*
Pregnancy	0.474 (0.171-1.309)	0.150
CAD	1.429 (1.090-1.872)	0.010
Seizures	1.129 (0.895-1.424)	0.305
Ischemic stroke	1.018 (0.732-1.416)	0.917
Hemorrhagic stroke	1.061 (0.816-1.378)	0.660
Skin lesions	0.682 (0.409-1.136)	0.141
Headache	0.951 (0.683-1.325)	0.768

Table 4: Etiology of All Cause 30-Day Readmission in CCMs

Readmission Diagnosis	Frequency (%)
Neurological Complications	33.9
Acute hemorrhagic cerebrovascular disease	5.2
Hemangioma of intracranial structures	5.0
Epilepsy; convulsions	4.9
Cerebral infarction	4.3
Traumatic brain injury (TBI); concussion, initial encounter	2.4
Headache; including migraine	2.4
Other specified nervous system disorders	3.0
Cardiac and circulatory congenital anomalies	1.8
Sequela of hemorrhagic cerebrovascular disease	1.4
Transient cerebral ischemia	1.3
Other specified congenital malformations of brain	1.0
Postprocedural or postoperative nervous system complication	1.0
Infectious Etiologies	14.6
Septicemia	8.3
Skin and subcutaneous tissue infections	2.3
Urinary tract infections	1.7
Pneumonia (except that caused by tuberculosis)	1.2
Intestinal infection	1.0
Gastrointestinal Complications	5.8
Gastrointestinal hemorrhage	1.8
Nausea and vomiting	1.0
Intestinal obstruction and ileus	0.9
Noninfectious gastroenteritis	0.7
Esophageal disorders	0.7
Gastrointestinal cancers - stomach	0.7
Cardiac Complications	5.4
Heart failure	2.1
Cardiac dysrhythmias	1.5
Syncope	1.0
Acute myocardial infarction	0.7
Pulmonary Complications	4.9
Chronic obstructive pulmonary disease and bronchiectasis	1.9
Acute pulmonary embolism	1.8
Respiratory failure; insufficiency; arrest	1.2
Other complications	35.5